United States Patent 5,439,901

United States Patent 5,439,901

United States Patent	5,439,901
Schwen, et. al.	Aug. 8, 1995

Cyproterone thiopivalate

Inventors:	Schwen; Richard J. (Cincinnati, OH); Sine; Mark R. (Morrow, OH); Warren; Raphael (Amberly Village, OH).
Assignee:	The Procter & Gamble Company (Cincinnati, OH).
Appl. No.:	096,081
Filed:	Jul. 23, 1993

Intl. Cl.:	A61K 31/56; C07J 7/00
U.S. Cl.:	514/178; 552/511
Field of Search:	552/585, 511; 514/181, 178; 424/449

References Cited

U.S. Patent Documents

3,234,093	Feb., 1966	Wierchert et al.	167/ 74
4,014,909	Mar., 1977	Torossian et al.	260/397
4,098,803	Jul., 1978	Torossian et al.	260/397.45
4,098,804	Jul., 1978	Torossian et al.	260/397.45
4,177,268	Dec., 1979	Torossian et al.	424/243
4,269,778	May, 1981	Torossian et al.	260/397.45
4,361,559	Nov., 1982	Varma	424/243
4,861,765	Aug., 1989	Mituskuchi et al.	514/181
4,877,781	Oct., 1989	LaHaye et al.	514/179
5,021,408	Jun., 1991	Aubard et al.	514/179

Foreign Patent Documents

0163490	Dec., 1985	EP
4006165A1	Feb., 1990	DE
86/01402	Mar., 1986	WO
93/13122	May, 1992	WO

Other References

Bettendorf, G., "Effect of Cyproterone in Female Virilizing Syndromes", Proceedings of 3rd Meeting of International Study Group on Steroid Hormones, vol. 3, pp. 267-276 (1968).
Bodor, N. "The Application of Soft Drug Approaches to the Design of Safer Corticosteroids", Topical Corticosteroid Therapy: A Novel Approach to Safer Drugs, pp. 13-25 (1988).

Bodor, N. "Soft Drugs: Principles and Methods for the Design of Safe Drugs", Medicinal Research Reviews, vol. 4, No. 4, pp. 449-469 (1984).

Bodor, N. and K. B. Sloan, "Soft Drugs V: Thiazolidine-Type Derivatives of Progesterone and Testosterone", Journal of Pharmaceutical Sciences, vol. 71, No. 5, pp. 514-520 (May 1982).

Burton, J. L., U. Laschet and S. Shuster, "Reduction of Sebum Excretion in Man by the Antiandrogen, Cyproterone Acetate", British Journal of Dermatology, vol. 89, pp. 487-490 (1973).

Chanoine, F. and J. L. Junien, "Comparative Pharmacokinetic Studies of Tixocortol Pivalate and Cortisol in the Rat", J. Steroid Biochem, vol. 21, No. 4, pp. 453-459 (1984).

Cunliffe, W. J., S. SHuster and A. J. Cassels Smith, "The Effect of Topical Cyproterone Acetate on Sebum Secretion in Patients With Acne", Br. J. Derm., vol. 81, No. 3, pp. 200-201 (1969).

Dawber, R. P. R., T. Sonnex and I. Ralfs, "Oral Anti-androgen Treatment of Common Baldness in Women", B. J. Derm., Suppl. 22, vol. 107, p. 20 (1982).

Devlin, R. G., A. Dean, K. Kripalani, J. R. Taylor and A. A. Sugerman, "Percutaneous Absorption and Adrenal Suppressive Potency of Tipredane, A New Topical Corticosteroid", J. Toxicol . . .--Cut, & Ocular Toxicol., vol. 5, No. 1, pp. 35-43 (1986).

Huber, J., R. Zeillinger, J. Spona, J. Schmidt, U. Tauber and W. Kuhnz, "Parenteral and Peroral Cyproterone Acetate (CPA) in Severe Hirsutism", Proceedings of World Congress of Dermatology, Berlin, May 24-29, 1987.

Lan, S. J., L. M. Scanlan, S. H. Weinstein, R. K. Varma, B. M. Warrack, S. E. Unger, M. A. Porubcan and B. H. Migdalof, "Biotransformation of Tipredane, A Novel Topical Steroid, In Mouse, Rat, and Human Liver Homogenates", Drug Metabolism and Disposition, vol. 17, No. 5, pp. 532-541, 1988.

Lan, S. J., L. M. Scanlan, J. Mitroka, S. H. Weinstein, B. N. Lutsky, C. A. Free, R. J. Wonjar, R. C. Millonig and B. H. Migdalof, "Rapid Metabolic Inactivation of Tipredane, A Structurally Novel Topical Steroid", Journal of Steroid Biochemistry, vol. 31, No. 5, pp. 825-834 (1988).

Larochelle, P., P. Du Souich, E. Bolte, J. Lelorier and R. Goyer, "Tixocortol Pivalate, a Corticosteroid With No Systemic Glucocorticoid Effect After Oral, Intrarectal, and Intranasal Application", Clin. Pharmacol. Ther., vol. 33, No. 3, pp. 343-350 (Mar. 1983).

Lutsky, B. N., R. C. Millonig, R. J. Wojnar, C. A. Free, R. G. Devlin, R. K. Varma and D. S. Karanewsky, "Androstene-17-thioketals", Arzneim.-Forsch./Drug Res., vol. 36(II), No. 12, pp. 1787-1795 (1986).

Lyons, F. and S. Shuster, "Indirect Evidence That The Action of Cyproterone Acetate On The Skin is Due To A Metabolite", Clinical Endocrinology, vol. 19, pp. 53-55 (1983).

Matias, J. and N. Orentreich, "The Effect of Androgens, Antiandrogens, and Vasodilating Agents on Hairloss in the Androchronogenetic Alopecia (AGA)--Mouse Model", Proceedings of World Congress of Dermatology, Berlin, May 24-29, 1987.

Neumann, F., R. von Berswordt-Wallrabe, W. Elger, H. Steinbeck, J. D. Hahn and M. Kramer, "Aspects of Androgen-Dependent Events as Studied by Antiandrogens", Recent Progress in Hormone Research, vol. 26, pp. 337-410 (1970).

Pye, R. J., J. L. Burton and J. I. Harris, "Effect of 1% Cyproterone Acetate in Cetomacrogol Cream BPC (Formula A) on Sebum Excretion Rate in Patients With Acne", British Journal of Dermatology, vol. 95, No. 4, pp. 427-428 (Oct. 1976).

Vermorken, A. J. M., "Reversal of Androgenic Alopecia by Minoxidil: Lack of Effect of Simultaneously Administered Intermediate Doses of Cyproterone Acetate", Acta Dermatovener, vol. 63, pp. 268-269 1982.

Voigt, W. and S. L. Hsia, "Further Studies on Testosterone 5().alpha. -Reductase of Human Skin", The Journal of Biological Chemistry, vol. 218, No. 12, pp. 4280-4285 (Jun. 1973).

Wendt, H., S. H. Hasan, I. Heinze and U. Tauber, "Systemic Effects of Local Antiandrogen Therapy", Arch Dermatol. Res., vol. 273, p. 171 (1982).

Wiechert, Neumann, "Cyproterone", The Merck Index, 11th Edition, p. 435 1989.

Wojnar, R. J., R. K. Varma, C. A. Free, R. C. Millonig, D. Karanewsky and B. N. Lutsky, "Androstene-17-thioketals", Arzneim.-Forsch./Drug. Res., vol. 36(II), No. 12, pp. 1782-1787 (1986).

Primary Examiner: Richter; Johann
Assistant Examiner: Cook; Rebecca
Attorney, Agent or Firm: Corstanje; Brahm J., Suter; David L., Rasser; Jacobus C.

Abstract

The present invention relates to the compound cyproterone thiopivalate (CTP) and compositions comprising CTP. The present invention further relates to methods of treating acne and/or sebaceous gland activity comprising topical application of CTP. The present invention additionally relates to methods of regulating hair growth comprising application of compositions comprising CTP.

5 Claims, No Drawings